AAPL 196.98 1.395% MSFT 367.78 -1.0307% NVDA 101.49 -2.8711% GOOGL 151.16 -1.4152% GOOG 153.36 -1.3762% AMZN 172.61 -0.9866% META 501.48 -0.1652% AVGO 170.99 -2.0732% LLY 839.96 14.2958% TSLA 241.37 -0.0745% TSM 151.74 0.0462% V 329.61 -0.5191% JPM 231.96 1.0235% UNH 454.11 -22.3797% NVO 58.08 -7.6336% WMT 93.22 2.2261% LVMUY 110.1 1.0741% XOM 106.92 2.6202% LVMHF 559.0 1.7288% MA 517.33 0.7596%
Last update at 2025-04-17T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Barclays Flags Medtronic, J&J as Most at Risk from Looming Pharma Tariffs
Wed 16 Apr 25, 08:56 PMATEC to Report First Quarter 2025 Financial Results on May 1, 2025
Mon 14 Apr 25, 01:00 PMInsiders Favor These 3 Leading Growth Stocks
Wed 02 Apr 25, 05:05 PMAlphatec Holdings Insider Buyers See Boost After Market Cap Rose US$134m
Fri 21 Mar 25, 07:37 PMATEC Prices Upsized $350.0 Million Convertible Senior Notes Offering
Wed 05 Mar 25, 03:54 AMATEC Announces Proposed Convertible Senior Notes Offering
Mon 03 Mar 25, 09:00 PMTop Growth Stocks With Insider Ownership For February 2025
Fri 28 Feb 25, 11:05 AMQ4 2024 Alphatec Holdings Inc Earnings Call
Thu 27 Feb 25, 12:10 PMAlphatec Holdings Inc (ATEC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Thu 27 Feb 25, 07:21 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -152.00900M | -144.16200M | -78.84900M | -57.14100M | -30.16900M |
| Minority interest | - | - | - | - | - |
| Net income | -152.14900M | -144.32600M | -78.99400M | -56.90200M | -28.97500M |
| Selling general administrative | 300.01M | 229.27M | 129.16M | 101.71M | 72.51M |
| Selling and marketing expenses | - | - | - | - | 72.51M |
| Gross profit | 233.06M | 157.76M | 102.50M | 77.59M | 63.24M |
| Reconciled depreciation | 43.93M | 30.17M | 11.63M | 8.51M | 6.79M |
| Ebit | -121.10200M | -108.87200M | -46.08800M | -38.66700M | -19.99400M |
| Ebitda | -110.51600M | -105.08700M | -45.40000M | -29.36000M | -19.25600M |
| Depreciation and amortization | 10.59M | 3.79M | 0.69M | 9.31M | 0.74M |
| Non operating income net other | - | - | - | -9.86500M | -0.59000M |
| Operating income | -121.10200M | -108.87200M | -46.08800M | -38.66700M | -22.44000M |
| Other operating expenses | 471.97M | 352.08M | 190.95M | 152.09M | 111.69M |
| Interest expense | 5.50M | 7.11M | 12.37M | 27.18M | 7.14M |
| Tax provision | 0.14M | 0.16M | 0.14M | -0.23900M | -1.36100M |
| Interest income | - | - | - | 9.87M | 7.14M |
| Net interest income | -5.50500M | -7.10800M | -12.37400M | - | -7.13900M |
| Extraordinary items | - | - | - | -0.10000M | -0.16700M |
| Non recurring | - | 8.06M | 4.22M | 0.06M | 2.45M |
| Other items | - | - | - | - | - |
| Income tax expense | 0.14M | 0.16M | 0.14M | -0.23900M | -1.36100M |
| Total revenue | 350.87M | 243.21M | 144.86M | 113.43M | 91.69M |
| Total operating expenses | 354.16M | 266.63M | 148.59M | 116.26M | 83.23M |
| Cost of revenue | 117.81M | 85.45M | 42.36M | 35.83M | 28.46M |
| Total other income expense net | -30.90700M | -35.29000M | -32.76100M | -18.47400M | -3.03600M |
| Discontinued operations | - | - | - | -0.10000M | -0.16700M |
| Net income from continuing ops | -152.14900M | -144.32600M | -78.99400M | -56.90200M | -28.80800M |
| Net income applicable to common shares | -152.14900M | -144.32600M | -78.99400M | -57.00200M | -42.46300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 805.21M | 513.38M | 572.05M | 261.22M | 169.95M |
| Intangible assets | 102.45M | 82.78M | 85.27M | 24.72M | 25.61M |
| Earning assets | - | - | - | - | - |
| Other current assets | 20.67M | 9.36M | 10.31M | 5.44M | 9.88M |
| Total liab | 703.49M | 550.09M | 492.63M | 131.34M | 126.32M |
| Total stockholder equity | 101.72M | -36.71300M | 79.42M | 129.88M | 43.63M |
| Deferred long term liab | - | 1.30M | - | - | - |
| Other current liab | 87.71M | 72.38M | 55.55M | 0.40M | 0.40M |
| Common stock | 0.01M | 0.01M | 0.01000M | 0.00800M | 0.00600M |
| Capital stock | 0.01M | 0.01M | 0.01000M | 0.00800M | 0.00600M |
| Retained earnings | -1118.96200M | -934.47400M | -782.32500M | -637.99900M | -558.92400M |
| Other liab | - | 11.54M | 367.93M | 8.63M | 11.95M |
| Good will | 73.00M | 39.77M | 39.69M | 13.90M | 13.90M |
| Other assets | 0.00000M | 4.87M | 3.25M | 1.78M | 0.55M |
| Cash | 220.97M | 84.70M | 187.25M | 107.77M | 47.11M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 157.57M | 138.87M | 101.09M | 58.31M | 36.39M |
| Current deferred revenue | 13.91M | 11.96M | 15.26M | 35.23M | 26.42M |
| Net debt | 320.71M | 311.17M | -182.69400M | -102.68000M | -45.31000M |
| Short term debt | 6.97M | 19.79M | 4.55M | 5.08M | 1.80M |
| Short long term debt | 1.81M | 14.95M | 0.34M | 4.20M | 0.49M |
| Short long term debt total | 541.68M | 395.86M | 4.55M | 5.08M | 1.80M |
| Other stockholder equity | 1205.39M | 884.84M | 844.13M | 743.06M | 577.86M |
| Property plant equipment | - | 130.31M | 112.68M | 36.67M | 19.72M |
| Total current assets | 451.09M | 255.63M | 331.16M | 184.16M | 108.32M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -159.26900M | -45.54100M | 114.91M | 28.66M |
| Short term investments | - | - | - | - | - |
| Net receivables | 72.61M | 60.06M | 41.89M | 24.60M | 16.15M |
| Long term debt | 511.04M | 349.51M | 326.49M | 38.03M | 53.45M |
| Inventory | 136.84M | 101.52M | 91.70M | 46.00M | 34.85M |
| Accounts payable | 48.98M | 34.74M | 25.74M | 17.60M | 7.77M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -8.32300M | -10.69000M | -5.99400M | 1.20M | 1.09M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.01000M | 0.00800M | 0.00600M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -782.32500M | -637.99900M | -558.92400M |
| Treasury stock | - | - | -25.09700M | -0.09700M | -0.09700M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.42M | 4.87M | 3.25M | 0.60M | 0.55M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 354.12M | 257.74M | 240.90M | 77.06M | 61.63M |
| Capital lease obligations | 28.84M | 31.40M | 28.59M | 0.93M | 2.24M |
| Long term debt total | - | - | 326.49M | 38.03M | 53.45M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -128.59700M | -58.28000M | -3.00000M | -23.85900M | -13.03200M |
| Change to liabilities | - | 7.52M | 12.59M | 14.02M | 8.25M |
| Total cashflows from investing activities | - | -58.28000M | -157.76200M | -23.85900M | -13.03200M |
| Net borrowings | - | 35.00M | 306.22M | 19.79M | 8.36M |
| Total cash from financing activities | 356.92M | 31.23M | 311.97M | 130.83M | 64.18M |
| Change to operating activities | - | 8.93M | 13.25M | 2.59M | 1.63M |
| Net income | -186.63800M | -152.14900M | -144.32600M | -78.99400M | -57.00200M |
| Change in cash | 136.27M | -102.55200M | 79.48M | 60.65M | 18.06M |
| Begin period cash flow | 84.70M | 187.25M | 107.77M | 47.11M | 29.05M |
| End period cash flow | 220.97M | 84.70M | 187.25M | 107.77M | 47.11M |
| Total cash from operating activities | -78.48500M | -75.14300M | -73.43200M | -46.41200M | -33.12100M |
| Issuance of capital stock | 67.43M | 57.51M | 131.83M | 111.04M | 55.83M |
| Depreciation | 59.68M | 43.93M | 30.17M | 11.63M | 8.51M |
| Other cashflows from investing activities | - | - | -86.21800M | -0.72800M | -2.98800M |
| Dividends paid | 1.06M | 3.04M | 316.25M | - | - |
| Change to inventory | -45.56200M | -20.70400M | -27.74600M | -18.19200M | -14.71200M |
| Change to account receivables | -12.79500M | -18.83200M | -10.14100M | -7.48400M | -1.29800M |
| Sale purchase of stock | -1.06400M | -3.04100M | -30.96300M | 111.04M | 55.83M |
| Other cashflows from financing activities | -4.85600M | -0.73100M | 572.35M | -0.05800M | 124.41M |
| Change to netincome | - | 54.13M | 59.88M | 31.51M | 21.80M |
| Capital expenditures | 86.97M | 58.28M | 68.54M | 23.89M | 13.03M |
| Change receivables | - | - | -10.14100M | -7.48400M | -1.29800M |
| Cash flows other operating | - | - | 7.69M | -2.19100M | -1.44600M |
| Exchange rate changes | - | - | -1.28900M | 0.09M | 0.03M |
| Cash and cash equivalents changes | - | - | 79.48M | 60.65M | 18.06M |
| Change in working capital | -54.17800M | -23.08900M | -23.87600M | -15.95300M | -8.37800M |
| Stock based compensation | 81.24M | 40.56M | 36.45M | 17.66M | 10.96M |
| Other non cash items | 21.41M | 15.61M | 4.59M | 19.23M | 13.23M |
| Free cash flow | -165.46000M | -133.42300M | -141.97600M | -70.29800M | -46.15300M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ATEC Alphatec Holdings Inc |
0.33 3.23% | 10.56 | - | - | 2.39 | 50.98 | 3.22 | -18.8885 |
| ABT Abbott Laboratories |
1.28 0.99% | 130.98 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-0.17 0.05% | 346.50 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
-0.1 0.12% | 82.60 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.13 0.14% | 95.12 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
1950 Camino Vida Roble, Carlsbad, CA, United States, 92008
| Name | Title | Year Born |
|---|---|---|
| Mr. Patrick S. Miles | Exec. Chairman, CEO & Pres | 1966 |
| Mr. J. Todd Koning | Exec. VP & CFO | 1973 |
| Mr. Craig E. Hunsaker | Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel | 1964 |
| Mr. Brian R. Snider | Exec. VP of Marketing | 1978 |
| Mr. David P. Sponsel | Exec. VP of Sales | 1979 |
| Mr. Jonathan Allen | Exec. VP of Commercial Operations | 1960 |
| Mr. Scott Lish | Sr. VP of R&D | 1982 |
| Dr. Luiz Pimenta | Chief Medical Officer | NA |
| Ms. Kelli Mari Howell | Exec. VP of Clinical Strategies | 1974 |
| Mr. Eric Dasso | Exec. VP of Adjunctive Technologies | 1974 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...